By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gen-Probe and DiagnoCure said today that Gen-Probe has received a regulatory medical device license from Health Canada, the Canadian government's department responsible for national public health, for a molecular urine test that determines the need for repeat biopsies for prostate cancer.

Gen-Probe exclusively licensed the worldwide rights to the PCA3 gene, on which its Progensa PCA3 assay is based, from its commercial partner DiagnoCure in 2003.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.